EU-LIFE

Building and promoting Excellence in Life Sciences in Europe
Building and promoting Excellence in Life Sciences in Europe

H2020 is mid-way and we are already looking far beyond

EU-LIFE Newsletter 3/2017

Latest News from EU-LIFE


R&I policy is like the fashion business: while users enjoy current outfit, experts are already fully into future seasons. This is to say that only mid-way of H2020, the next FP9 is already at the core of policy discussion.

Key needs identified by EU-LIFE are: to increase overall budget for FP9 when compared to H2020, to increase support to basic research inside FP9, redefinition of impact, redefinition of effective interaction between research and innovation.

The EU-LIFE Coordinator and Chairs, in close collaboration with the BoD and Strategy group have been setting EU-LIFE position on FP9. We are having indebt discussions regarding EU-LIFE position on which H2020 schemes should be kept, discontinued or significantly changed in FP9. ERC, Marie Curie, research infrastructure, collaborative projects, widening are at the top of the list for discussion.

We are meeting with relevant members at the European Commission, Parliament and Council to advocate for our vision. Recently, Marta Agostinho was invited to contribute as expert in the Bohemia study, a Delphi study which will further advise the EC. 

You may wish to consult H2020 interim evaluation stakeholders’ consultations result and follow release of the Report on Contribution of R&I to European Competitiveness, by the High Level Group on maximising the impact of European research and innovation programmes on 3rd July 2017 in Brussels at the conference “Research & Innovation: Shaping our future.”

EU-LIFE position statements: eu-life.eu/tags/publication 

Image: H2020 is mid-way and we are already looking far beyond. Credits: European Commission.